EUCTR2015-002427-26-FR进行中（未招募）1 期
A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180) - Study of Pembrolizumab in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects must:
- •- Be = 18 years of age on the day of signing the informed consent.
- •- Have an ECOG performance status of 0 or 1.
- •- Have a life expectancy greater than 3 months.
- •- Have histologically proven advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ.
- •- Have experienced documented objective radiographic or clinical disease progression during or after receiving two lines of locally or globally recommended therapies.
- •- Have measurable disease based on RECIST 1.1 as determined by central imaging vendor assessment.
- •- Provide a tissue sample for intratumoral immune-related GEP and PD-L1 by Immunohistochemistry analysis.
- •- Have demonstrated adequate organ function.
- •- Negative pregnancy test for females of child bearing potential prior to starting study and male and female subjects of childbearing potential must be willing to use an adequate method of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The subject will be excluded from participating in the trial if the subject:
- •- Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of treatment.
- •- Has an active autoimmune disease that has required systemic treatment in past 2 years.
- •- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •- Has had prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.
- •- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or if the subject has previously participated in Merck pembrolizumab (MK-3475) clinical trials.
- •- Has a diagnosed additional malignancy within 5 years prior to treatment allocation with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers.
- •- Has received a live vaccine within 30 days of planned start of study therapy.
- •- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- •- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •- Has known history of, or any evidence of interstitial lung disease or active, non-infectious pneumonitis.
- •- Has an active infection requiring systemic therapy.
- •- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
- •- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
研究者
相似试验
进行中（未招募）
1 期
A Phase II study of Pembrolizumab in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusMedDRA version: 21.0 Level: PT Classification code 10030155 Term: Oesophageal carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Esophageal CarcinomaEUCTR2015-002427-26-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
A Phase II study of Pembrolizumab in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusEsophageal CarcinomaEUCTR2015-002427-26-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
A Phase II study of Pembrolizumab in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the OesophagusOesophageal CarcinomaMedDRA version: 21.0Level: PTClassification code 10030155Term: Oesophageal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002427-26-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerEUCTR2014-003574-16-FRMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.270
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerEUCTR2014-003574-16-LTMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.253